Gland Pharma Reports 97% Surge in Q4 Profit, Driving Stock Up 12.37%
Gland Pharma spurts as Q4 PAT jumps 97% YoY to Rs 367 crore
Image: Business Standard
Gland Pharma's consolidated net profit surged 96.62% year-on-year to ₹366.7 crore in Q4 FY26, driven by a 22.31% increase in net sales to ₹1,742.80 crore. The company launched five new products in the U.S. and reported significant growth across various international markets, bolstering investor confidence.
- 01Revenue from the U.S. market reached ₹980.7 crore, a 25.44% increase year-on-year.
- 02Profit before tax rose to ₹505.79 crore, marking a 75.42% increase from the previous year.
- 03Gland Pharma launched a total of 31 new products in the U.S. during FY26.
- 04The company’s consolidated EBITDA was ₹513 crore, with an EBITDA margin of 29%.
- 05A final dividend of ₹20 per equity share has been proposed for FY26.
Advertisement
In-Article Ad
Gland Pharma, based in Hyderabad, reported a remarkable 96.62% increase in consolidated net profit to ₹366.7 crore for Q4 FY26, driven by a 22.31% rise in net sales, totaling ₹1,742.80 crore. The company's revenue from the U.S. market alone grew to ₹980.7 crore, up 25.44% year-on-year, while European sales surged by 36% to ₹381.4 crore. Profit before tax also saw a significant increase, reaching ₹505.79 crore, reflecting a 75.42% rise from the previous year. Gland Pharma's consolidated EBITDA stood at ₹513 crore, with an EBITDA margin of 29%. The company launched five new products in the U.S. during the quarter, contributing to a total of 31 new launches for the fiscal year. Additionally, Gland Pharma has proposed a final dividend of ₹20 per equity share, which, if approved, will be paid within 30 days of the upcoming Annual General Meeting. Executive Chairman Srinivas Sadu emphasized the company's strong performance and ongoing growth in the CDMO segment, which is expected to drive future profitability.
Advertisement
In-Article Ad
The significant profit increase and proposed dividend may boost investor confidence and attract more investments, impacting stock performance positively.
Advertisement
In-Article Ad
Reader Poll
Do you think Gland Pharma's growth will continue in the next fiscal year?
Connecting to poll...
More about Gland Pharma
Nifty Index Declines Amid Global Weakness and Consumer Durables Slide
Business Standard • May 18, 2026
Gland Pharma Shares Surge 16% to Record High Following Strong Q4 Results
Business Standard • May 18, 2026
Gland Pharma Shares Surge 16% to Record High Amid Market Turmoil: Investment Insights
Mint • May 18, 2026
Read the original article
Visit the source for the complete story.